CONTEXT: The contribution of autoimmunity to the multisystem dysregulation that characterizes the frailty syndrome in older adults is unknown. OBJECTIVE: The aim of the study was to investigate the relationship between thyroid antibodies and frailty in older women. DESIGN, SETTING, AND PARTICIPANTS: We conducted a cross-sectional study nested within the Women's Health and Aging Studies I and II. Thyroglobulin antibodies (TgAbs), thyroid peroxidase antibodies (TPOAbs), and antinuclear antibodies were measured in the baseline sera of 641 community-dwelling older women. MAIN OUTCOME MEASURE: Frailty was defined using a validated five-component measure. RESULTS: The prevalence of prefrailty and frailty was lower in TgAb-positive than negative older women (37.1 vs. 47.8% and 6.7 vs.11.9%, respectively; P = 0.01 and 0.03). The prevalence of prefrailty, but not frailty, was lower in TPOAb-positive than negative women (38.9 vs. 48.0% and 10.1 vs. 11.3%; P = 0.04 and 0.34). After adjustment for covariates including serum thyroid stimulation hormone concentration and thyroid medication usage in multinomial regression models, TgAb-positive older women had lower odds of prefrailty and frailty compared with TgAb-negative women (odds ratio 0.57 and 0.30; 95% confidence interval 0.34-0.98 and 0.10-0.85, respectively). Similarly, TPOAb-positive older women had lower odds of frailty compared with TPOAb-negative women (odds ratio 0.44; 95% confidence interval 0.20-0.96). These trends were not observed with antinuclear antibodies. CONCLUSION: Independent of thyroid function status, community-dwelling older women who are seropositive for TgAbs and TPOAbs are less likely to be frail than seronegative women.
CONTEXT: The contribution of autoimmunity to the multisystem dysregulation that characterizes the frailty syndrome in older adults is unknown. OBJECTIVE: The aim of the study was to investigate the relationship between thyroid antibodies and frailty in older women. DESIGN, SETTING, AND PARTICIPANTS: We conducted a cross-sectional study nested within the Women's Health and Aging Studies I and II. Thyroglobulin antibodies (TgAbs), thyroid peroxidase antibodies (TPOAbs), and antinuclear antibodies were measured in the baseline sera of 641 community-dwelling older women. MAIN OUTCOME MEASURE: Frailty was defined using a validated five-component measure. RESULTS: The prevalence of prefrailty and frailty was lower in TgAb-positive than negative older women (37.1 vs. 47.8% and 6.7 vs.11.9%, respectively; P = 0.01 and 0.03). The prevalence of prefrailty, but not frailty, was lower in TPOAb-positive than negative women (38.9 vs. 48.0% and 10.1 vs. 11.3%; P = 0.04 and 0.34). After adjustment for covariates including serum thyroid stimulation hormone concentration and thyroid medication usage in multinomial regression models, TgAb-positive older women had lower odds of prefrailty and frailty compared with TgAb-negative women (odds ratio 0.57 and 0.30; 95% confidence interval 0.34-0.98 and 0.10-0.85, respectively). Similarly, TPOAb-positive older women had lower odds of frailty compared with TPOAb-negative women (odds ratio 0.44; 95% confidence interval 0.20-0.96). These trends were not observed with antinuclear antibodies. CONCLUSION: Independent of thyroid function status, community-dwelling older women who are seropositive for TgAbs and TPOAbs are less likely to be frail than seronegative women.
Authors: A B Newman; J S Gottdiener; M A Mcburnie; C H Hirsch; W J Kop; R Tracy; J D Walston; L P Fried Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Linda P Fried; Luigi Ferrucci; Jonathan Darer; Jeff D Williamson; Gerard Anderson Journal: J Gerontol A Biol Sci Med Sci Date: 2004-03 Impact factor: 6.053
Authors: Jeremy Walston; Mary Ann McBurnie; Anne Newman; Russell P Tracy; Willem J Kop; Calvin H Hirsch; John Gottdiener; Linda P Fried Journal: Arch Intern Med Date: 2002-11-11
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Joseph G Hollowell; Norman W Staehling; W Dana Flanders; W Harry Hannon; Elaine W Gunter; Carole A Spencer; Lewis E Braverman Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Luca Chiovato; Francesco Latrofa; Lewis E Braverman; Furio Pacini; Marco Capezzone; Lucio Masserini; Lucia Grasso; Aldo Pinchera Journal: Ann Intern Med Date: 2003-09-02 Impact factor: 25.391
Authors: M Matejková-Behanová; V Zamrazil; K Vondra; J Vrbíková; P Kucera; M Hill; M Andel Journal: J Endocrinol Invest Date: 2002-10 Impact factor: 4.256
Authors: Vanessa S Virgini; Nicolas Rodondi; Peggy M Cawthon; Stephanie Litwack Harrison; Andrew R Hoffman; Eric S Orwoll; Kristine E Ensrud; Douglas C Bauer Journal: J Clin Endocrinol Metab Date: 2015-10-23 Impact factor: 5.958
Authors: Irina A Pashnina; Irina M Krivolapova; Tamara V Fedotkina; Varvara A Ryabkova; Margarita V Chereshneva; Leonid P Churilov; Valeriy A Chereshnev Journal: Antibodies (Basel) Date: 2021-02-25
Authors: Jody C Miller; Sue O MacDonell; Andrew R Gray; Malcolm R Reid; David J Barr; Christine D Thomson; Lisa A Houghton Journal: Nutrients Date: 2016-07-23 Impact factor: 5.717
Authors: Kim Bouillon; Mika Kivimaki; Mark Hamer; Severine Sabia; Eleonor I Fransson; Archana Singh-Manoux; Catharine R Gale; G David Batty Journal: BMC Geriatr Date: 2013-06-21 Impact factor: 3.921